Alison Gulbis

4.7k total citations · 1 hit paper
72 papers, 2.6k citations indexed

About

Alison Gulbis is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, Alison Gulbis has authored 72 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 25 papers in Hematology and 17 papers in Genetics. Recurrent topics in Alison Gulbis's work include Chronic Lymphocytic Leukemia Research (16 papers), Hematopoietic Stem Cell Transplantation (15 papers) and Lymphoma Diagnosis and Treatment (14 papers). Alison Gulbis is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Hematopoietic Stem Cell Transplantation (15 papers) and Lymphoma Diagnosis and Treatment (14 papers). Alison Gulbis collaborates with scholars based in United States, Belgium and Canada. Alison Gulbis's co-authors include Elizabeth J. Shpall, Katayoun Rezvani, Partow Kebriaei, Nitin Jain, Patrick Hwu, Sattva S. Neelapu, Sherry Adkins, Yi Lin, Frederick L. Locke and Sudhakar Tummala and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Alison Gulbis

66 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

2017 1.6k citations Sattva S. Neelapu, Sudhakar Tummala et al. Nature Reviews Clinical Oncology profile →

Peers

Countries citing papers authored by Alison Gulbis

Since Specialization

Citations

This map shows the geographic impact of Alison Gulbis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Gulbis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Gulbis more than expected).

Fields of papers citing papers by Alison Gulbis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Gulbis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Gulbis. The network helps show where Alison Gulbis may publish in the future.

Co-authorship network of co-authors of Alison Gulbis

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Gulbis. A scholar is included among the top collaborators of Alison Gulbis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Gulbis. Alison Gulbis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Results of Ipilimumab Alternating with Lenalidomide in Patients with Relapsed Lymphoma Who Underwent Hematopoietic Cell Transplantation 2025 ·Transplantation and Cellular Therapy ·(unknown), Padmanee Sharma, Denái R. Milton, Alison Gulbis, Fadi Haddad, Richard E. Champlin, Ken H. Young, Issa F. Khouri	0
2	Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma 2025 ·Clinical Cancer Research ·Yago Nieto, Jeremy Ramdial, Benigno C. Valdez, Peter F. Thall, Roland L. Bassett, M. J. Barnett, Samer A. Srour, Chitra Hosing, Amin M. Alousi, Muzaffar H. Qazilbash, Uday Popat, Alison Gulbis, Terri Lynn Shigle, Sairah Ahmed, (unknown), Richard E. Champlin, Elizabeth J. Shpall, Börje S. Andersson	1
3	Seizure Prophylaxis and its Impact on Busulfan Pharmacokinetics and Dosing in a Novel Timed Sequential Protocol: MD Anderson Experience 2025 ·Transplantation and Cellular Therapy ·Jitesh D. Kawedia, (unknown), Alan L. Myers, Alison Gulbis, Rohtesh S. Mehta, Richard E. Champlin, Elizabeth J. Shpall, Yago Nieto, Börje S. Andersson, Uday Popat	0
4	Enabling efficient patient discharge with a mindset, toolset, and skillset framework. 2024 ·JCO Oncology Practice ·(unknown), (unknown), Amin M. Alousi, (unknown), Jennifer Freeman, (unknown), (unknown), (unknown), Alison Gulbis, (unknown), (unknown), Christopher R. Flowers, William G. Wierda, Elizabeth J. Shpall	0
5	Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant 2023 ·Bone Marrow Transplantation ·Taha Al‐Juhaishi, Yingjun Wang, Denái R. Milton, Zijun Y. Xu‐Monette, Elias Jabbour, May Daher, Jin S. Im, Qaiser Bashir, Swaminathan P. Iyer, David Marín, Amanda Olson, Uday Popat, Muzaffar H. Qazilbash, Gabriela Rondón, Alison Gulbis, Richard E. Champlin, Ken H. Young, Issa F. Khouri	3
6	Decrease post-transplant relapse using donor-derived expanded NK-cells 2021 ·Leukemia ·Stefan O. Ciurea, Piyanuch Kongtim, Doris Soebbing, Prashant Trikha, Gregory K. Behbehani, Gabriela Rondón, Amanda Olson, Qaiser Bashir, Alison Gulbis, Indreshpal Kaur, Katayoun Rezvani, Elizabeth J. Shpall, Roland L. Bassett, Kai Cao, Andrew St. Martin, Steven M. Devine, Mary Horowitz, Marcelo C. Pasquini, Dean A. Lee, Richard E. Champlin	65
7	Levofloxacin versus Cefpodoxime for Antibacterial Prophylaxis in Allogeneic Stem Cell Transplantation 2019 ·Biology of Blood and Marrow Transplantation ·(unknown), (unknown), Alison Gulbis, Samuel L Aitken, Ella Ariza‐Heredia, Sairah Ahmed	14
8	Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation 2018 ·Biology of Blood and Marrow Transplantation ·Sita Bhella, Navneet S. Majhail, (unknown), Luciano J. Costa, Andrew Daly, Christopher E. Dandoy, Zachariah DeFilipp, (unknown), Alison Gulbis, Lisa K. Hicks, Mark Juckett, Nandita Khera, Amrita Krishnan, George B. Selby, Nirav N. Shah, Melisa Stricherz, Auro Viswabandya, Christopher Bredeson, Matthew D. Seftel	31
9	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' 2018 ·Nature Reviews Clinical Oncology ·Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William G. Wierda, Frederick L. Locke, Yi Lin, Nitin Jain, Naval Daver, Alison Gulbis, Sherry Adkins, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall	102
10	Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation 2017 ·Blood ·Stefan O. Ciurea, Jolie Schafer, Roland L. Bassett, Cecele J. Denman, Kai Cao, (unknown), Gabriela Rondón, Julianne Chen, Doris Soebbing, Indreshpal Kaur, Alison Gulbis, Sairah Ahmed, Katayoun Rezvani, Elizabeth J. Shpall, Dean A. Lee, Richard E. Champlin	250
11	Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results 2017 ·Blood ·Issa F. Khouri, Elias Jabbour, Celina Ledesma, Martin Körbling, Amin M. Alousi, Paolo Anderlini, Betül Oran, Stefan O. Ciurea, Luis Fayad, Roland L. Bassett, Alison Gulbis	1
12	Safety of Addition of Inotuzumab Ozogamicin (CMC 544) to Bendamustine, Fludarabine, and Rituximab (BFR) Allogeneic Conditioning for Lymphoid Malignancies 2017 ·Blood ·Issa F. Khouri, Alison Gulbis, Denái R. Milton, Martin Körbling, Celina Ledesma, Sairah Ahmed, Amin M. Alousi, Betül Oran, Paolo Anderlini, Stefan O. Ciurea, Roland L. Bassett, Elias Jabbour	0
13	Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation 2017 ·Biology of Blood and Marrow Transplantation ·Aimee Hammerstrom, (unknown), Sai Ravi Pingali, Gabriela Rondón, Julianne Chen, Denái R. Milton, Roy F. Chemaly, Richard E. Champlin, Alison Gulbis, Stefan O. Ciurea	37
14	High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan 2017 ·The Lancet Haematology ·Yago Nieto, Benigno C. Valdez, Sai Ravi Pingali, Roland L. Bassett, Ruby Delgado, John Nguyen, Nina Shah, Uday Popat, Roy B. Jones, Börje S. Andersson, Alison Gulbis, Sairah Ahmed, Qaiser Bashir, Simrit Parmar, Krina K. Patel, Alan L. Myers, Gabriela Rondón, Robert Z. Orlowski, Richard E. Champlin, Muzaffar H. Qazilbash	13
15	Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience 2016 ·Antiviral Research ·(unknown), Firas El Chaer, (unknown), Dimpy P. Shah, Ella Ariza‐Heredia, Victor E. Mulanovich, Alison Gulbis, Elizabeth J. Shpall, Roy F. Chemaly	31
16	Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis 2014 ·Leukemia & lymphoma ·Michelle Poon, Patricia S. Fox, Barry I. Samuels, Susan O’Brien, Elias Jabbour, Yvonne Hsu, Alison Gulbis, Martin Körbling, Richard Champlin, Lynne V. Abruzzo, Roland L. Bassett, Issa F. Khouri	9
17	Retrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients 2011 ·American Journal of Hematology ·(unknown), Alison Gulbis, Richard E. Champlin, Muzaffar H. Qazilbash	9
18	Busulfan and Metronidazole: An Often Forgotten but Significant Drug Interaction 2011 ·Annals of Pharmacotherapy ·Alison Gulbis, Kirk S. Culotta, Roy B. Jones, Börje S. Andersson	27
19	[Endoscopic sphincterotomy. A Belgian experience (1976) (author's transl)]. 1977 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Michel Cremer, Alison Gulbis, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
20	La cholangiographie et la wirsungographie endoscopiques 1972 ·Acta Endoscopica ·Alison Gulbis, Michel Cremer, L Engelholm	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact